IL2 and cancer: With respect to cancer migration, molecular regulators, such as CXCR4 and CXCR7, were reduced by IL-2/sorafenib co-treatment and were reversed to near-normal levels after the inactivation of the JNK-TAZ pathways (Fig. 7f–h).